UHPLC-Qtrap-MS/MS法研究灯盏细辛成分在血管性痴呆模型大鼠的药代动力学及网络药理学

Pharmacokinetic and Network Pharmacology Studies for the Prototype Components of Erigeron Breviscapus in Rat Model of Vascular Dementia Using UHPLC-Qtrap-MS/MS

  • 摘要: 采用超高效液相色谱-串联四极杆-线性离子阱质谱(UHPLC-Qtrap-MS/MS)技术对芹菜素、野黄芩苷、丁香酸、水杨酸、芹菜素-7-O-葡萄糖醛酸苷、东莨菪亭等6种灯盏细辛入血成分在血管性痴呆(VaD)模型大鼠血浆中的含量变化进行定量分析,并进行药代动力学参数计算。以0.05%甲酸-水和乙腈为流动相,在ACQUITY UPLC HSS T3 色谱柱(100 mm×2.1 mm, 1.8 μm)上梯度洗脱;采用多反应监测(MRM)模式,电喷雾离子源(ESI)进行质谱检测;随后使用DAS2.0软件进行药代动力学参数计算。结合入血成分分析结果,采用网络药理学方法构建入血成分-疾病靶点-代谢通路网络,推测潜在作用靶点。结果表明,在VaD模型组中,丁香酸、野黄芩苷、东莨菪亭、水杨酸的体内暴露量均低于假手术组,可能存在代谢加快或排泄增加的现象;而野黄芩苷、水杨酸、芹菜素-7-O-葡萄糖醛酸苷在大鼠体内存在双峰吸收,可能存在肝肠循环现象;在所有入血成分中,野黄芩苷的体内暴露量最高。网络药理学研究发现,灯盏细辛主要入血成分共作用于12个疾病靶点,与5条信号通路有关;其中,药效成分野黄芩苷主要通过作用于丝裂原活化蛋白激酶(MAPK)信号通路对VaD产生干预作用。本研究可为灯盏细辛的药代动力学研究提供支持,同时对深入理解其作用机制提供参考。

     

    Abstract: The whole dried plant of Erigeron breviscapus is clinically used in traditional Chinese medicine, and named as “Deng-Zhan-Xi-Xin”. The herb is primarily distributed in Yunnan, Guangxi, and Guizhou provinces of China, and its traditional therapeutic effects include promoting blood circulation, unblocking meridians, relieving pain, dispelling wind and cold. Nowadays, it is commonly prescribed for pathological conditions including hemiplegia, coronary heart disease, cerebral thrombosis, rheumatism, and microcirculatory disorders. Pharmacological studies have demonstrated its neuroprotective effects, such as microcirculation improvement, lipid-lowering activity, and inhibition of platelet aggregation. Chemical components including caffeoyl acid and its analogues, as well as flavonoids and their glycosides, have been reported, and the flavonoid glycoside of scutellarin has regarded as an active component related to the efficacy of the herb. Current in vivo pharmacokinetic studies on E. breviscapus have mostly focused on its injectable formulations or pure compounds in normal rats, while multi-component pharmacokinetic studies of its aqueous decoction in vascular dementia (VaD) rat models remain insufficient. As a result, the study established a bilateral common carotid artery occlusion-induced VaD rat model, which better represented clinical cases. The pharmacokinetics of multiple blood-absorbed components from the aqueous decoction was investigated by ultra-high performance liquid chromatography coupled with quadrupole-linear ion trap mass spectrometry (UHPLC-Qtrap-MS/MS). Furthermore, network pharmacology analysis was employed to predict the potential targets of these components, and interaction networking for compound-protein-pathway was constructed. The UHPLC-Qtrap-MS/MS technique was employed to quantitatively analyze the content changes of six components, including apigenin, scutellarin, syringic acid, salicylic acid, apigenin-7-O-glucuronide and scopoletin in the plasma of rat model of vascular dementia. Additionally, the pharmacokinetic parameters were calculated. A gradient elution was performed on an ACQUITY UPLC HSS T3 chromatographic column (100 mm×2.1 mm, 1.8 μm), using 0.05% formic acid-water as mobile phase A and acetonitrile as mobile phase B. A quantitative analytical method was established by optimizing declustering potential (DP) and collision energy (CE) values, followed by comprehensive methodological validation covering specificity, linearity, precision, accuracy, stability, extraction recovery, and matrix effects. Mass spectrometry detection was conducted under multi-reaction monitoring (MRM) mode with electrospray ionization source (ESI). Subsequently, the DAS 2.0 software was utilized to calculate detailed pharmacokinetic parameters. The network pharmacology method was applied to construct a network of chemical components-disease targets-metabolic pathways. Based on the blood-absorbed components, the potential active targets were inferred. The analysis results showed that, compared with the sham-operated group, the in vivo exposure of syringic acid, scutellarin, scopoletin, and salicylic acid in the vascular dementia model group is lower, which may be attributed to accelerated metabolism and increased excretion of these components. Additionally, scutellarin, salicylic acid, and apigenin-7-O-glucuronide exhibites a double-peak absorption, suggesting a possible enterohepatic circulation phenomenon. Among all detected active components, scutellarin has the highest in vivo exposure. Network pharmacology analysis revealed that the components act on a total of 12 disease targets and are related to 5 signaling pathways. The active ingredient scutellarin mainly exertes a therapeutic effect on vascular dementia by acting on the mitogen-activated protein kinase (MAPK) signaling pathway. The potential multi-target mechanisms of E. breviscapus via network pharmacology remains experimental validation in future. These rational findings provide support for the pharmacokinetic study of E. breviscapus and offer a reference for deeper understanding of its mechanism of action.

     

/

返回文章
返回